Microneedle patch comprising semaglutide
The microneedle patch with directly connected hydrophilic microneedles and a specific adhesive composition addresses adhesive force issues, enhancing drug delivery and compliance by ensuring effective skin adherence and minimal semaglutide residue.
Patent Information
- Application Number
- PCT/KR2026/006080
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-15
- Filing Date
- 2026-05-14
- Publication Date
- 2026-11-19
AI Technical Summary
Existing microneedle patches for semaglutide delivery suffer from insufficient adhesive force, leading to reduced drug delivery efficacy due to hydrophilic microneedles not adhering properly to the skin, and issues with semaglutide loss and patient compliance with injectable medications.
A microneedle patch design where hydrophilic microneedles are directly connected to an adhesive sheet, eliminating the need for a hydrophilic support film, and utilizing an adhesive composition with hydrophilic polymers like sodium alginate and poloxamer to enhance adhesion and biodegradability, ensuring effective skin adherence and reduced semaglutide residue.
The patch achieves enhanced drug delivery capability and minimizes semaglutide loss, improving patient compliance by ensuring better adhesion and reducing residual drug amount to 28.71% or less after application.
Smart Images

Figure KR2026006080_19112026_PF_FP_ABST
Abstract
Description
Microneedle patch containing semaglutide
[0001] The present invention relates to a microneedle patch comprising semaglutide, and more specifically, provides a microneedle patch comprising semaglutide, and furthermore, to a microneedle patch comprising semaglutide in which microneedles can be directly attached to an adhesive sheet without a support film supporting hydrophilic microneedles.
[0002] Glucagon-like peptide-1 (GLP-1) is derived from pre-pro-glucagon, a 158-amino acid precursor polypeptide processed in different tissues, and forms numerous different pro-glucagon-derived peptides, including glucagon, glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-2), and oxintomodulin (OXM), which are involved in the regulation of food intake as well as various physiological functions including glucose homeostasis, insulin secretion, gastric emptying, and intestinal growth.
[0003] GLP-1 is produced as a 37-amino acid peptide corresponding to amino acids 72 to 108 of proglucagon (92 to 128 of preproglucagon). GLP-1(7-36) amide or GLP-1(7-37) acid is a biologically active form of GLP-1 that exhibits essentially equivalent activity at the GLP-1 receptor.
[0004] GLP-1 and GLP-1 analogs acting as agonists on GLP-1 receptors have been found to provide effective blood glucose control for treating, for example, patients with type 2 diabetes, as well as provide weight loss effects, preservation of beta-cell function, and relief of hypertension, hypoglycemia, and / or hyperlipidemia.
[0005] Byetta ® Bydureon ® & Bydurepn PEN ® & Bydureon BCise ® (Exenatide), Ozempic® & Wegovy ® (Semaglutide), Victoza ® & Saxenda ® (Liraglutide), Adlyxin ® (Lixisenatide), Tanzeum ® (albiglutide), and Trulicity ® Certain GLP-1 analogs, including dulaglutide, are commercially available or under development.
[0006] These semaglutides are primarily administered to the human body as oral or injectables. Semaglutides can be enzymatically degraded in the gastrointestinal tract and intestinal mucosa, and may be insufficiently absorbed from the intestinal mucosa. Additionally, parenteral administration is preferable to oral administration due to various barriers, such as first-pass metabolism in the liver.
[0007] Meanwhile, injectable medications have problems such as causing pain to patients receiving them, raising concerns about secondary infections, and generating medical waste. Additionally, in the case of self-injection, patients must inject themselves, which leads to poor medication adherence due to fear and reluctance, and consequently reduces the effectiveness of treatment.
[0008] Therefore, there is a need to develop a microneedle patch formulation of semaglutide; in particular, there is a requirement for a patch formulation that can reduce semaglutide loss by minimizing the amount of semaglutide remaining in the needles after application to the skin.
[0009] Meanwhile, microneedle patches developed to date have primarily been used for in vivo drug delivery, blood collection, and the detection of analytes within the body. Metals and various polymer materials have been used as microneedle materials. Recently, biodegradable polymer materials have been gaining attention as microneedle materials.
[0010] FIG. 1 is a drawing and photograph illustrating a microneedle patch (1000) including a microneedle (14) according to the prior art. FIG. 1 (A) is a side cross-sectional view of a microneedle patch (1000) according to the prior art, FIG. 1 (B) is a state in which a protective release film (11) has been removed from the microneedle patch (1000), FIG. 1 (C) is a photograph showing the adhesive sheet (6) and a support sheet (12) provided on the upper surface of the adhesive sheet (6) from the side, and FIG. 1 (D) is a planar photograph of the adhesive sheet (6) and the support sheet (12) viewed from above.
[0011] Referring to FIG. 1, the microneedle patch (1000) comprises an adhesive sheet (6), a support film (12) provided on the upper surface of the adhesive sheet (6), and microneedles (14) provided on the upper surface of the support film (12). Furthermore, the microneedle patch (1000) may further comprise a protective release film (11) disposed to surround the support film (12) on the upper surface of the adhesive sheet (6).
[0012] The adhesive sheet (6) provides adhesive force to allow the micro-needles (14) to adhere to the user's skin. Before using the micro-needle patch (1000), the adhesive sheet (6) is covered by the aforementioned protective release film (11), and when using it, the user removes the protective release film (11) (state (B) of FIG. 1) and exposes the adhesive sheet (6).
[0013] The support film (12) is provided on the upper surface of the adhesive sheet (6) and serves as a support on which the micro-needles (14) are formed. The micro-needles (14) may be made of a hydrophilic or water-soluble material. Additionally, the adhesive sheet (6) may be made of a hydrophobic material to maintain adhesive strength.
[0014] In this case, since the hydrophilic microneedles (14) are not attached to the hydrophobic adhesive sheet (6) with sufficient bonding force, conventionally, a hydrophilic support film (12) is first formed or attached to the upper surface of the adhesive sheet (6), and then the microneedles (14) are formed on the upper surface of the support film (12). Figures (C) and (D) of FIG. 1 illustrate a state in which a support film (12) is provided on the upper surface of the adhesive sheet (6).
[0015] When a hydrophilic support film (12) is provided in this manner, microneedles (14) can be formed on the aforementioned support film (12) as shown in FIG. 2.
[0016] In the case of the microneedle patch (1000) according to the prior art of the structure described above, as explained earlier, when in use, the protective release film (11) is removed to expose the adhesive sheet (6). However, since the support film (12) for forming the microneedle (14) is provided on the upper surface of the adhesive sheet (6), the adhesive sheet (6) that is actually exposed corresponds to the edge area (A) of the upper surface of the adhesive sheet (6), as shown in (B) of FIG. 1.
[0017] That is, when a microneedle patch (1000) according to the prior art is attached to the skin of the human body, only the edge area (A) of the upper surface of the adhesive sheet (6) is attached to the human body, and the area of the support film (12) where the microneedle (14) is formed is not exposed to the adhesive sheet (6), so the adhesive force does not act directly. Consequently, in the structure according to the prior art, the adhesive force for attaching the microneedle (14) to the skin is insufficient, so the microneedle (14) does not adhere to the skin, resulting in a problem where the drug delivery ability is significantly reduced.
[0018] The present invention aims to provide a microneedle patch capable of administering semaglutide more effectively to the human body in order to solve the above-mentioned problems.
[0019] In addition, the present invention aims to provide a microneedle patch capable of adhering the microneedles to the skin when the microneedle patch is attached to a user's skin.
[0020] The objective of the present invention as described above can be achieved by a microneedle patch characterized by an adhesive sheet, a hydrophilic microneedle provided on the adhesive sheet and comprising a semaglutide, wherein the microneedle is directly connected to one surface of the adhesive sheet.
[0021] According to the present invention having the aforementioned configuration, when administering semaglutide to the human body, a larger amount can be administered more effectively by means of a microneedle patch.
[0022] In addition, according to the present invention, when a microneedle patch is attached to a user's skin, the adhesive sheet between the microneedles is exposed so that the microneedles can be effectively adhered to the skin.
[0023] FIG. 1 is a drawing illustrating a microneedle patch according to the prior art,
[0024] Fig. 2 is a photograph of the microneedle in Fig. 1.
[0025] FIG. 3 is a drawing illustrating a microneedle patch according to an embodiment of the present invention.
[0026] Fig. 4 is a photograph of the microneedle taken in Fig. 3,
[0027] FIG. 5 is a drawing illustrating a method of manufacturing a microneedle patch according to an embodiment of the present invention by a blowing tension method.
[0028] FIG. 6 is a schematic diagram illustrating a method of fabricating a microneedle patch having the configuration according to FIG. 3 by a mold method.
[0029] FIG. 7 is a side cross-sectional view illustrating the composition of the adhesive layer,
[0030] FIG. 8 is a photograph of microneedles formed on an adhesive sheet containing various hydrophilic polymers,
[0031] Fig. 9 is a photograph showing a state where the microneedles are not formed accurately.
[0032] FIG. 10 is a photograph showing whether microneedles are formed according to the change in contact angle based on the content of a hydrophilic polymer in an adhesive sheet according to the present invention and an adhesive sheet according to the prior art when a microneedle patch is fabricated by a blowing tension method.
[0033] FIG. 11 is a photograph showing the degree of microneedle formation according to the viscosity of the hydrophilic polymer when a microneedle patch is fabricated by a blowing tension method.
[0034] FIG. 12 is a photograph showing whether an adhesive sheet containing sodium alginate is carbonized according to the weight ratio of poloxamer to the adhesive composition.
[0035] FIG. 13 is a perspective view illustrating a two-layer microneedle structure,
[0036] Figure 14 is a photograph showing the degree of formation of microneedles according to the weight ratio of calcium chloride when a microneedle patch is produced by a blowing tension method.
[0037] The microneedle patch of the present invention comprises an adhesive sheet, a hydrophilic microneedle comprising semaglutide provided on the adhesive sheet, and the microneedle may be directly connected to one surface of the adhesive sheet.
[0038] Here, the hydrophilic microneedles are composed of a plurality of units, and the adhesive sheet can be exposed between the plurality of microneedles.
[0039] Furthermore, the adhesive sheet may include a hydrophilic polymer.
[0040] In this case, the adhesive sheet is formed from an adhesive composition containing the hydrophilic polymer and an adhesive, and includes an adhesive layer to which the microneedles are connected, and a film layer provided on the lower part of the adhesive layer, wherein the hydrophilic polymer may be included in an amount of 5 to 40 weight% in the adhesive composition.
[0041] For example, the hydrophilic polymer may be composed of one or more mixtures selected from CMC (carboxymethyl cellulose), Carbomer, HPMC (hydroxypropyl methyl cellulose), PVP (polyvinyl pyrrolidone), PVA (polyvinyl alcohol), Guar Gum, sodium alginate, and poloxamer.
[0042] In addition, the adhesive may comprise 10 to 50 weight% of synthetic rubber, 30 to 70 weight% of hydrogenated hydrocarbon resin, 5 to 20 weight% of mineral oil, and 0.2 to 3 weight% of an antioxidant.
[0043] Meanwhile, the contact angle of the adhesive sheet may be 70° to 100°.
[0044] Furthermore, the viscosity of the hydrophilic polymer may be 5 mPa·s to 5,000 mPa·s.
[0045] In addition, the hydrophilic polymer may include sodium alginate and poloxamer, and the adhesive composition may include 22 to 30 weight% of sodium alginate and 0.1 to 0.5 weight% of poloxamer.
[0046] In this case, the microneedles may include calcium chloride (CaCl2) along with a polymer material having biocompatibility and biodegradability.
[0047] Furthermore, the calcium chloride may be included in the microneedle in an amount of 10 to 20 weight percent.
[0048] Meanwhile, the microneedle may have a drug-loading layer and a base layer below the drug-loading layer, the drug-loading layer may include an active ingredient together with a polymer material having biocompatibility and biodegradability, and the base layer may include calcium chloride together with the polymer material having biocompatibility and biodegradability.
[0049] In this case, the calcium chloride may be included in the base layer in an amount of 10 to 20 weight percent.
[0050] Furthermore, when the above microneedle patch is attached to the human body and removed after a predetermined time, the residual amount of semaglutide may be 28.71% or less.
[0051] Meanwhile, the objective of the present invention as described above can be achieved by an adhesive composition for forming an adhesive layer of an adhesive sheet included in a microneedle patch, wherein the composition comprises a hydrophilic polymer, the hydrophilic polymer comprises sodium alginate and poloxamer, and the adhesive composition comprises 22 to 30 weight% of sodium alginate and 0.1 to 0.5 weight% of poloxamer.
[0052] Hereinafter, a microneedle patch according to an embodiment of the present invention will be examined in detail with reference to the drawings.
[0053] FIG. 3 is a drawing illustrating a microneedle patch (2000) according to an embodiment of the present invention, and FIG. 4 corresponds to a photograph of the microneedle (14) actually taken in FIG. 3. FIG. 3 (A) is a side cross-sectional view of the microneedle patch (2000) according to the present invention, FIG. 3 (B) is a side cross-sectional view illustrating the state in which the protective release film (11) has been removed from the microneedle patch (2000), FIG. 3 (C) is a photograph showing the adhesive sheet (10) from the side, and FIG. 3 (D) is a planar photograph of the adhesive sheet (10) viewed from above.
[0054] Referring to FIGS. 3 and 4, the microneedle patch (2000) may have an adhesive sheet (10) and microneedles (14) provided on the adhesive sheet (10).
[0055] Here, the microneedle (14) is inserted into the skin and dissolved, and may be made of a polymer material having biocompatibility and biodegradability, and a water-soluble or hydrophilic polymer material.
[0056] For example, a biocompatible and biodegradable polymer material capable of constituting the microneedle (14) may be hyaluronic acid and its salt, polyvinylpyrrolidone, polyvinyl alcohol, cellulose polymer, dextran, gelatin, glycerin, polyethylene glycol, polysorbate, propylene glycol, povidone, carbomer, gum ghatti, guar gum, glucomannan, glucosamine, dammer resin, rennet casein, locust bean gum, microfibrillated cellulose, psyllium seed gum, xanthan gum, arabino galactan, gum arabic, alginic acid, gelatin, gellan gum, carrageenan, karaya gum, curdlan, It may be composed of one or more selected from chitosan, chitin, tara gum, tamarind gum, tragacanth gum, furcelleran, pectin or pullulan, hydroxypropyl methylcellulose, hydroxyalkyl cellulose, ethyl hydroxyethyl cellulose, alkylcellulose, sodium chondroitin sulfate, and carboxymethylcellulose, and furthermore, calcium chloride (CaCl2) may be used together with the above polymer material.
[0057] Meanwhile, in the present invention, the micro-needles (14) may be directly connected to or formed on the upper surface or one surface of the adhesive sheet (10). That is, the micro-needles (14) may be directly formed or attached to the upper surface of the adhesive sheet (10). Looking at (C) and (D) of FIG. 3, it can be seen that there is no hydrophilic support film on the upper surface of the adhesive sheet (10) as in the prior art. In addition, as shown in FIG. 4, it can be seen that the micro-needles are normally attached and provided on the upper surface of the adhesive sheet (10) without a hydrophilic support film.
[0058] In this way, when the micro-needles (14) are directly provided on the upper surface of the adhesive sheet (10) or when the micro-needles (14) are composed of a plurality of them, the adhesive sheet (10) between the plurality of micro-needles (14) can be exposed as shown in (A) and (B) of FIG. 3.
[0059] That is, when a user removes the protective release film (11) as in (B) of FIG. 3 to use the microneedle patch (2000), the adhesive sheet (10) between the microneedles (14) as well as the edge area of the adhesive sheet (10) may be exposed.
[0060] Accordingly, when the upper surface of the adhesive sheet (10) equipped with the microneedles (14) is attached to the skin of the human body, the adhesive sheet (10) is exposed between the microneedles (14) along with the edge area of the adhesive sheet (10), allowing the microneedles (14) to adhere more effectively to the skin of the human body. In this case, drugs or the like can be delivered more effectively to the human body through the microneedles (14), thereby greatly increasing the drug delivery capability of the microneedle patch (2000).
[0061] Meanwhile, FIG. 5 is a drawing illustrating a method for manufacturing a microneedle patch (2000, 2000') according to the present invention. The above method corresponds to the droplet extension (DEN) method developed by the applicant. Regarding microneedles manufactured by the droplet extension method, reference may be made to Korean registered patents No. 1254240, No. 1285085, No. 1636069, No. 1816922, No. 2103194, and No. 2127123, the entire contents of which may be incorporated herein by reference.
[0062] Referring to FIG. 5, the step of manufacturing the microneedle patch (2000, 2000') may include first providing a pair of adhesive sheets (10, 10') and spotting a biodegradable viscous material (13, 13') on at least one of the pair of adhesive sheets (10, 10').
[0063] The adhesive sheet (10, 10') may be provided, for example, on a pair of substrates (not shown). In this case, the adhesive sheet (10, 10') may be provided by applying and drying it on the substrates, or it may be provided in a sheet state.
[0064] In the present invention, as previously described, a hydrophilic support film can be omitted on the mutually opposing surfaces of the adhesive sheets (10, 10'). By doing so, microneedles (14, 14') can be directly formed on the mutually opposing surfaces (upper surfaces) of the adhesive sheets (10, 10').
[0065] Meanwhile, in FIG. 5 (A), the viscous material (13, 13') is shown spotted on both of the pair of adhesive sheets (10, 10'), but is not limited thereto. For example, it is also possible to spot the viscous material (13, 13') on only one of the pair of adhesive sheets (10, 10').
[0066] Next, the pair of adhesive sheets (10, 10') are moved relative to each other ((A) in FIG. 5) so that they come closer together, and the viscous material (13, 13') is brought into contact with each other between the pair of adhesive sheets (10, 10'), and the pair of adhesive sheets (10, 10') are separated to tension the viscous material (13, 13') ((B) in FIG. 3).
[0067] In this way, when the pair of adhesive sheets (10, 10') are separated from each other, if the bonding force between the viscous material (13, 13') forming the microneedles and the pair of adhesive sheets (10, 10') is weak, the viscous material (13, 13') may not be stretched during the tensioning step (B) of FIG. 3 and the viscous material (13, 13') may be separated from the pair of adhesive sheets (10, 10'). In the present invention, by including a hydrophilic polymer in the adhesive sheets (10, 10'), the bonding force between the viscous material (13, 13') forming the microneedles and the pair of adhesive sheets (10, 10') is maintained.
[0068] That is, the adhesive force between the viscous material (13, 13') and the pair of adhesive sheets (10, 10') can be determined to be sufficient for the viscous material (13, 13') to form an advanced portion, or greater than that.
[0069] Next, the viscous material (13, 13') is solidified and the pair of adhesive sheets (10, 10') are separated to form microneedles (14, 14') directly on the pair of adhesive sheets (10, 10').
[0070] In this case, the viscous material (13, 13') can be solidified by means such as blowing air. After the viscous material (13, 13') has sufficiently solidified, if the pair of adhesive sheets (10, 10') are further separated, the viscous material (13, 13') that was connected to each other is separated, forming a microneedle (14, 14') having a tip, and a microneedle patch (2000, 2000') is completed ((C) of FIG. 3).
[0071] Meanwhile, the composition for making a microneedle patch constituting the viscous material (13, 13') may include semaglutide. In this case, the weight ratio of the semaglutide and the biodegradable polymer material in the composition for making a microneedle patch may be 1:1.1 to 2.9, 1:1.2 to 2.8, 1:1.3 to 2.7, 1:1.4 to 2.6, 1:1.5 to 2.5, or 1:1.6 to 2.4.
[0072] Furthermore, the composition for producing the microneedle patch may further include an additive to increase the solubility of semaglutide. The additive may be, for example, at least one selected from the group consisting of disodium phosphate (Na2HPO4) and NaOH (sodium hydroxide). The disodium phosphate may be included in an amount of 0.5 to 2 weight percent relative to the total weight of the composition for producing the microneedle patch. The NaOH may be included in an amount of 0.1 to 0.25 weight percent relative to the total weight of the composition for producing the microneedle patch.
[0073] Additionally, the composition for producing the microneedle patch may further include at least one selected from the group consisting of trehalose and dextran. The trehalose may be included in an amount of 0.1 to 5 weight%, 1 to 4 weight%, or 1.5 to 4.5 weight% relative to the total weight of the composition for producing the microneedle patch. The dextran may be included in an amount of 0.1 to 6 weight%, 0.5 to 5 weight%, or 1 to 4.5 weight% relative to the total weight of the composition for producing the microneedle patch.
[0074] Meanwhile, as described above, since the micro-needle (14) has water-soluble or hydrophilic properties, if the adhesive sheet (10) has hydrophobic properties as in the prior art, the bonding force between the micro-needle (14) and the adhesive sheet (10) becomes very low. In this case, when producing a micro-needle patch (2000) using the air-pull tension method according to FIG. 5 described above, if the adhesive sheets (10) are separated on both sides, the viscous material (13, 13') between the adhesive sheets (10) cannot be stretched on both sides, and the viscous material (13, 13') may be separated from one of the adhesive sheets (10) so that the micro-needle (14) is not formed.
[0075] These problems can occur not only in the method of producing a microneedle patch according to the aforementioned air-blowing tension method, but also in the case of producing it by a mold method. Fig. 6 schematically illustrates a method of producing a microneedle patch having the configuration according to Fig. 3 by a mold method.
[0076] Referring to FIG. 6, when a microneedle patch is manufactured by a mold method, a needle composition (400) is placed in a cavity (310) of a mold (300), an adhesive sheet (410) is provided on top of it, and the needle composition (400) is dried through drying or appropriate heat treatment. Subsequently, when the needle composition (400) is dried, the adhesive sheet (410) is pulled to separate it from the mold (300).
[0077] In this way, when the adhesive sheet (410) is separated from the mold (300), if the bonding force between the adhesive sheet (410) and the micro needles (420) is weak, some of the micro needles (420A) among the micro needles (420) may not be separated from the mold (300), and only the adhesive sheet (410) may be separated.
[0078] The present invention provides an adhesive sheet and an adhesive composition capable of maintaining the bonding force between the adhesive sheet (10) and the hydrophilic microneedle (14) to the extent that a microneedle patch (2000) can be manufactured, and further maintaining the adhesive force so that the adhesive sheet (10) can be firmly attached to the skin of the human body. This will be examined in detail below.
[0079] FIG. 7 is a side cross-sectional view illustrating an adhesive sheet (10) according to the present invention. In FIG. 7, the micro-needles (14) are omitted.
[0080] Referring to FIG. 7, the adhesive sheet (10) may have an adhesive layer (10A) and a film layer (10B) provided below the adhesive layer (10A). The aforementioned micro-needles (14) are provided on the upper surface of the adhesive layer (10A).
[0081] The above film layer (10B) may include at least one of, for example, a PET (polyester) film and a PU (polyurethane) film. However, the above film layer (10B) is not limited to the aforementioned types and can be implemented in various ways.
[0082] Meanwhile, the adhesive layer (10A) may be formed from an adhesive composition, wherein the adhesive composition may include a hydrophilic polymer and an adhesive. That is, in the present invention, the adhesive layer (10A) of the adhesive sheet (10) is produced by an adhesive composition containing a hydrophilic polymer.
[0083] Accordingly, the adhesive layer (10A) becomes hydrophilic, and accordingly, the adhesive sheet (10) to which the microneedle (14) is attached becomes hydrophilic. When the adhesive sheet (10) or the adhesive layer (10A) becomes hydrophilic, the bonding force between the adhesive sheet (10) and the microneedle (14) can be sufficiently maintained even when the microneedle (14) is formed on the upper surface of the adhesive layer (10A).
[0084] According to the inventor's experiments, it is preferable that the hydrophilic polymer be included in the adhesive composition in an amount of 5 to 40 weight percent. If the hydrophilic polymer is included in the adhesive composition in an amount of less than 5 weight percent, the bonding force between the adhesive layer (10A) and the microneedle (14) is weak, making it difficult to form a microneedle patch (2000). Additionally, if the hydrophilic polymer is included in the adhesive composition in an amount exceeding 40 weight percent, the adhesive force of the adhesive layer (10A) becomes very weak, making it difficult to attach the microneedle patch (2000) to the skin of the human body.
[0085] For example, the hydrophilic polymer may be composed of one or more mixtures selected from CMC (carboxymethyl cellulose), Carbomer, HPMC (hydroxypropyl methyl cellulose), PVP (polyvinyl pyrrolidone), PVA (polyvinyl alcohol), Guar Gum, sodium alginate, and poloxamer.
[0086] Meanwhile, the aforementioned adhesive may comprise 10 to 50 weight% of synthetic rubber, 30 to 70 weight% of hydrogenated hydrocarbon resin, 5 to 20 weight% of mineral oil, and 0.2 to 3 weight% of an antioxidant.
[0087] FIG. 8 is a photograph showing the state in which microneedles are formed on the upper surface of an adhesive sheet (10) containing a hydrophilic polymer according to the present invention.
[0088] Referring to FIG. 8, FIG. 8 (A) contains CMC (carboxymethyl cellulose) as a hydrophilic polymer, FIG. 8 (B) contains Carbomer as a hydrophilic polymer, FIG. 8 (C) contains HPMC (hydroxypropyl methyl cellulose) as a hydrophilic polymer, FIG. 8 (D) contains PVP (polyvinyl pyrrolidone) as a hydrophilic polymer, and FIG. 8 (E) contains PVA (polyvinyl alcohol) as a hydrophilic polymer.
[0089] The inventors included each of the previously described hydrophilic polymers in the adhesive composition at a concentration of 5 to 40 weight% and produced a microneedle patch by the air-blowing tension method according to FIG. 5.
[0090] As shown in FIG. 8, when a microneedle patch (2000) is manufactured using an adhesive sheet (10) according to the present invention, it can be seen that the adhesive sheet (10) and the microneedle (14) are not separated and are manufactured normally.
[0091] Meanwhile, FIG. 9 is a photograph showing a case where a microneedle patch is fabricated by the air-drying method according to FIG. 5 when the content of the hydrophilic polymer in the adhesive composition is less than the aforementioned 5 weight%. FIG. 9 (A) is a case where no hydrophilic polymer is included, and FIG. 9 (B) is a case where Guar Gum is included in the hydrophilic polymer at less than 5 weight%.
[0092] As shown in FIG. 9, when the hydrophilic polymer included in the adhesive composition is less than the aforementioned 5 weight percent, the bonding force between the adhesive layer (10A) of the adhesive sheet (10) and the microneedle (14) is weakened. Therefore, when the microneedle patch (2000) is manufactured using the blowing tension method according to FIG. 5, as previously discussed, the viscous composition (13, 13') (see FIG. 5) is not tensioned and is separated from one side of the pair of adhesive sheets (10) to form a microneedle (14).
[0093] Meanwhile, the contact angle of the adhesive sheet (10) according to the present invention may be 70° to 100°. Here, the contact angle can be defined as the angle formed between the liquid-gas interface and the liquid-solid interface when a liquid droplet, such as a water droplet, exists on a solid.
[0094] FIG. 10 is a photograph showing whether microneedles (14) are formed according to the change in contact angle according to the content of hydrophilic polymer in the adhesive sheet (10) according to the present invention and the adhesive sheet according to the prior art when a microneedle patch is produced by the blowing tension method according to FIG. 5.
[0095] Figures 10 (A), (B), (C), and (D) show the state in which the contact angle is measured, and Figures 10 (E), (F), (G), and (H) show whether microneedles are formed when a microneedle patch is fabricated according to the method according to Figure 5 according to the corresponding contact angle. For example, Figure 10 (E) corresponds to Figure 10 (A), Figure 10 (F) corresponds to Figure 10 (B), Figure 10 (G) corresponds to Figure 10 (C), and Figure 10 (H) corresponds to Figure 10 (D).
[0096] (A) of FIG. 10 corresponds to a hydrophilic polymer content of less than 5 weight%, and the measured contact angle corresponds to approximately 100° or more. In this case, as shown in (E) of FIG. 10, it can be seen that the tip is not properly formed at the end of the microneedle (14), and the microneedle formation rate corresponds to approximately 20%, which is very low.
[0097] In addition, (B) of FIG. 10 corresponds to a hydrophilic polymer content of 5% to 20% by weight, and the measured contact angle corresponds to approximately 90° to 100°. In this case, as shown in (F) of FIG. 10, it can be seen that a tip is normally formed at the end of the microneedle (14), and the microneedle formation rate corresponds to approximately 100%, so it can be seen that almost all microneedles are normally formed.
[0098] Likewise, (C) of FIG. 10 corresponds to a hydrophilic polymer content of 20% to 40% by weight, and the measured contact angle corresponds to approximately 70° to 90°. In this case, as shown in (G) of FIG. 10, it can be seen that a tip is normally formed at the end of the microneedle (14), and the microneedle formation rate corresponds to approximately 100%, so it can be seen that almost all microneedles are normally formed.
[0099] Meanwhile, (D) of FIG. 10 corresponds to a hydrophilic polymer content of more than 40 weight%, and the measured contact angle corresponds to approximately 60° or less. In this case, as shown in (H) of FIG. 10, it can be seen that the microneedles (14) are not properly formed, and the microneedle formation rate corresponds to approximately 40%, which is very low.
[0100] Meanwhile, the viscosity of the hydrophilic polymer included in the adhesive composition may be 5 mPa·s to 5,000 mPa·s.
[0101] FIG. 11 is a photograph showing the degree of formation of microneedles (14) according to the viscosity of the hydrophilic polymer when a microneedle patch is produced by the air-blowing tension method according to FIG. 5.
[0102] (A) of FIG. 11 shows that the viscosity of the hydrophilic polymer is approximately 5 mPa·s to 1,000 mPa·s, and in this case, the tip is normally formed at the end of the microneedle (14), and the microneedle formation rate is approximately 100%, so it can be seen that almost all microneedles are normally formed.
[0103] In addition, (B) of FIG. 11 shows that the viscosity of the hydrophilic polymer is approximately 3,000 mPa·s to 5,000 mPa·s, and in this case, the tip is normally formed at the end of the microneedle (14), and the microneedle formation rate is approximately 95%, so it can be seen that almost all microneedles are normally formed.
[0104] On the other hand, (C) and (D) of FIG. 11 show that the viscosity of the hydrophilic polymer is approximately 10,000 mPa·s to 14,000 mPa·s and 30,000 mPa·s to 45,000 mPa·s, respectively, and in this case, it can be seen that the tip is not normally formed at the end of the microneedle (14), and the microneedle formation rate is approximately 65% and 50%, respectively, and it can be seen that the microneedle is not normally formed.
[0105] Meanwhile, as described above, the above adhesive composition contains 5 to 40 weight percent of the hydrophilic polymer, and the hydrophilic polymer may include sodium alginate and poloxamer.
[0106] For example, the sodium alginate in the adhesive composition may be included in an amount of approximately 22 to 30 weight percent, preferably 24 weight percent. If the sodium alginate is included in an amount less than 22 weight percent, it may be difficult to produce micro-needles according to the blowing tension method according to FIG. 5, whereas if the sodium alginate is included in an amount more than 30 weight percent, the adhesive strength of the adhesive sheet may be weakened.
[0107] In addition, the sodium alginate is susceptible to heat and may carbonize; to prevent this, the poloxamer may be included as a heat stabilizer.
[0108] In this case, the poloxamer may be included in the adhesive composition in an amount of approximately 0.1 to 0.5 weight%, and preferably in an amount of 0.2 weight%. If the poloxamer is included in an amount less than 0.1 weight%, it is difficult to prevent carbonization of the sodium alginate, whereas if the poloxamer is included in an amount more than 0.5 weight%, it may be difficult to produce microneedles due to the wettability of the poloxamer.
[0109] Meanwhile, FIG. 12 corresponds to a photograph showing whether the adhesive sheet containing sodium alginate is carbonized according to the weight ratio of the poloxamer to the adhesive composition. FIG. 12 corresponds to the case where the adhesive composition contains approximately 24% by weight of sodium alginate.
[0110] Fig. 12 (A) represents the case where the poloxamer is not included (0 wt%), Fig. 12 (B) represents the case where the poloxamer is included at 0.05 wt%, Fig. 12 (C) represents the case where the poloxamer is included at 0.10 wt%, Fig. 12 (D) represents the case where the poloxamer is included at 0.15 wt%, Fig. 12 (E) represents the case where the poloxamer is included at 0.20 wt%, and Fig. 12 (F) represents the case where the poloxamer is included at 0.30 wt%.
[0111] As shown in FIG. 12, it can be seen that carbonization occurs in all of the adhesive sheets in cases (A) to (D) of FIG. 12. On the other hand, it can be seen that carbonization does not occur in the adhesive sheets in cases (E) and (F) of FIG. 12.
[0112] In addition, when the sodium alginate and the poloxamer are used as the hydrophilic polymers of the adhesive composition, the microneedles may include calcium chloride (CaCl2) along with a polymer material having biocompatibility and biodegradability.
[0113] For example, hyaluronic acid may be used as the polymer material having the above-mentioned biocompatibility and biodegradability, and calcium chloride may be used together with the hyaluronic acid. However, the hyaluronic acid is merely described as an example, and one or more of the aforementioned polymer materials having biocompatibility and biodegradability may be used.
[0114] In this case, when the microneedle patch is fabricated according to the air-blowing tension method of Fig. 5 described above, the following reaction can be induced.
[0115] [Chemical Formula 1]
[0116]
[0117] That is, by providing adhesive force to the microneedles through the Ca(Alginate) component generated by the cross-linking reaction according to [Chemical Formula 1] above, it is possible to prevent the microneedles from separating from the adhesive sheet even when the microneedle patch is fabricated according to the blowing tension method of Fig. 5.
[0118] The calcium chloride may be included in the microneedle in an amount of 10 to 20 weight%, preferably in an amount of 15 to 20 weight%.
[0119] Additionally, the microneedles may be composed of a multilayer structure. FIG. 13 illustrates a microneedle (14) composed of a multilayer structure. FIG. 13 illustrates, for example, a case where the microneedle (14) is composed of a two-layer structure.
[0120] Referring to FIG. 13, the microneedle (14) may have a drug-loading layer (142) and a base layer (144) provided below the drug-loading layer (142).
[0121] In this case, the drug loading layer (142) may include an active ingredient along with the aforementioned biocompatible and biodegradable polymer material.
[0122] Additionally, the base layer (144) may include calcium chloride along with the aforementioned biocompatible and biodegradable polymer material. The calcium chloride in the base layer (144) may be included in an amount of 10 to 20 weight%, and preferably in an amount of 15 to 20 weight%.
[0123] The width (W) of the base layer (144) may be, for example, 400 μm to 1,400 μm, and the height (H) of the base layer (144) may be 30 μm to 300 μm.
[0124] Meanwhile, Fig. 14 is a photograph showing the degree of formation of microneedles (14) according to the weight ratio of calcium chloride when a microneedle patch is produced by the blowing tension method according to Fig. 5.
[0125] Fig. 14 (A) represents the case where the microneedle does not contain calcium chloride (0 wt%), Fig. 14 (B) represents the case where the microneedle contains 5 wt% of calcium chloride, Fig. 14 (C) represents the case where the microneedle contains 10 wt% of calcium chloride, Fig. 14 (D) represents the case where the microneedle contains 15 wt% of calcium chloride, and Fig. 14 (E) represents the case where the microneedle contains 20 wt% of calcium chloride.
[0126] Looking at Fig. 14, it can be seen that when the calcium chloride is not included (Fig. 14 (A)) or when the calcium chloride is included at 5% by weight (Fig. 14 (B)), the microneedles are not formed normally.
[0127] In addition, when the calcium chloride is included at 10% by weight ((C) of FIG. 14), the microneedles are formed, but it can be seen that the uniformity in height and diameter is somewhat reduced.
[0128] On the other hand, when the calcium chloride is included at 15% by weight (Fig. 14 (D)) and when the calcium chloride is included at 20% by weight (Fig. 14 (E)), it can be seen that the microneedles are formed normally and the height and diameter are constant.
[0129] Meanwhile, the inventors conducted an experiment to evaluate the residual amount of semaglutide in a microneedle patch without a support film containing semaglutide according to the present invention (Example) and a microneedle patch containing semaglutide equipped with a support film manufactured according to the prior art (Comparative Example).
[0130] In the case of the microneedle patch according to the above example, it was manufactured using the aforementioned composition and manufacturing method, and in the case of the microneedle patch according to the above comparative example, a hydrophilic support film was attached to the upper surface of a hydrophobic adhesive sheet, and then hydrophilic or water-soluble microneedles were manufactured on the upper surface of the support film. In the above comparative example, the adhesive sheet does not contain a hydrophilic polymer material, and the microneedle itself containing semaglutide was manufactured in the same way as in the example.
[0131] [Table 1] below represents the results of evaluating the residual amount (%) of semaglutide remaining in the patch after attaching a microneedle patch containing semaglutide according to the examples and comparative examples to pig skin and human skin and removing it after a certain period of time.
[0132] Patch Type Pig Skin (600㎛) Pig Skin (800㎛) Human Skin (Cadaver) Example 32.86% 32.73% 28.71% Comparative Example 42.78% 54.72% 40.57%
[0133] Specifically, the microneedles were inserted into the skin of hairless minipigs under 12 months of age with different thicknesses (600㎛, 800㎛), removed after 8 hours, and the patch attachment site was wiped with gauze. The removed patch was then analyzed using HPLC (Manufacturer: Agilent) to calculate the concentration of semaglutide. Similarly, the microneedles were inserted into a cadaver, removed after 8 hours, and the patch attachment site was wiped with gauze. The removed patch was then analyzed using HPLC (Manufacturer: Agilent) to calculate the concentration of semaglutide.
[0134] Looking at [Table 1] above, it can be seen that the microneedle patch according to the example shows a residual amount of approximately 32% regardless of the thickness of the pig skin, and in particular, in the case of a cadaver, only a very small amount remains with a residual amount of 28.71%.
[0135] On the other hand, in the case of the microneedle patch according to the comparative example, it can be seen that the residue increases as the pig skin becomes thicker, and in particular, in the case of a cadaver, it shows a relatively very high residue of 40.57%.
[0136] Ultimately, it can be seen that when using the microneedle patch according to the embodiment of the present invention, the residual amount of semaglutide is very low at 28.71%, which indicates that a relatively larger amount of semaglutide can be administered to the human body compared to the comparative example.
[0137] Although the present invention has been described above with reference to preferred embodiments, those skilled in the art may modify and change the present invention in various ways without departing from the spirit and scope of the invention as described in the claims below. Therefore, if a modified embodiment basically includes the components of the claims of the present invention, it should be considered to be included within the technical scope of the present invention.
[0138]
[0139] [Explanation of the symbol]
[0140] 10 : Adhesive sheet
[0141] 11 : Protective release film
[0142] 14 : Microneedles
[0143] 300 : Mold
[0144] 310 : Cavity
[0145] 400: Needle composition
[0146] 2000 : Microneedle patch
Claims
1. Adhesive sheet; Hydrophilic microneedles comprising semaglutide, provided on the above adhesive sheet; Equipped with, A microneedle patch characterized in that the microneedles are directly connected to one surface of the adhesive sheet.
2. In Paragraph 1, The above hydrophilic microneedles are composed of a plurality of, A microneedle patch characterized by the adhesive sheet being exposed between the plurality of microneedles.
3. In Paragraph 1 or 2, A microneedle patch characterized in that the adhesive sheet comprises a hydrophilic polymer.
4. In Paragraph 3, The above adhesive sheet is An adhesive layer formed from an adhesive composition comprising the above hydrophilic polymer and an adhesive, wherein the microneedles are connected; and A film layer provided below the adhesive layer; Includes, A microneedle patch characterized by the above adhesive composition containing 5 to 40 weight percent of the hydrophilic polymer.
5. In Paragraph 4, A microneedle patch characterized in that the hydrophilic polymer is composed of one or more mixtures selected from CMC (carboxymethyl cellulose), Carbomer, HPMC (hydroxypropyl methyl cellulose), PVP (polyvinyl pyrrolidone), PVA (polyvinyl alcohol), Guar Gum, sodium alginate, and poloxamer.
6. In Paragraph 4, The above adhesive A microneedle patch characterized by comprising 10 to 50 weight% of synthetic rubber, 30 to 70 weight% of hydrogenated hydrocarbon resin, 5 to 20 weight% of mineral oil, and 0.2 to 3 weight% of an antioxidant.
7. In Paragraph 4, A microneedle patch characterized by the contact angle of the adhesive sheet being 70° to 100°.
8. In Paragraph 4, A microneedle patch characterized by the viscosity of the hydrophilic polymer being 5 mPa·s to 5,000 mPa·s.
9. In Paragraph 4, The above hydrophilic polymer includes sodium alginate and poloxamer, A microneedle patch characterized in that the above adhesive composition comprises 22 to 30 weight% of sodium alginate and 0.1 to 0.5 weight% of poloxamer.
10. In Paragraph 9, A microneedle patch characterized by the above microneedles comprising calcium chloride (CaCl2) together with a biocompatible and biodegradable polymer material.
11. In Paragraph 10, A microneedle patch characterized by containing 10 to 20 weight percent of calcium chloride in the microneedles.
12. In Paragraph 9, The above microneedles Drug loading layer; and A base layer provided at the bottom of the above drug loading layer; Equipped with, The above drug loading layer contains an active ingredient along with a polymer material having biocompatibility and biodegradability, and A microneedle patch characterized in that the base layer comprises calcium chloride together with the biocompatible and biodegradable polymer material.
13. In Paragraph 12, A microneedle patch characterized by the calcium chloride being included in the base layer in an amount of 10 to 20 weight percent.
14. In Paragraph 1, A microneedle patch characterized by having a residual amount of semaglutide of 28.71% or less when the microneedle patch is attached to the human body and removed after a predetermined time.
15. An adhesive composition for forming an adhesive layer of an adhesive sheet included in a microneedle patch, The above composition includes a hydrophilic polymer, and The above hydrophilic polymer includes sodium alginate and poloxamer, An adhesive composition characterized by comprising 22 to 30 weight% of sodium alginate and 0.1 to 0.5 weight% of poloxamer in the adhesive composition.
